Genesis Biomed plans to open a $27 million investment vehicle in 2021

A Spanish consulting firm, that specializes in the biomedical sector, has opened a new office on Velázquez Street in Madrid, and is preparing two new investments during this year. Genesis Biomed, The Catalan consulting firm founded in 2017, is starting new projects in 2020 and plans to open a new investment vehicle of $27 million (€25 million) in 2021.

“It is a first estimate and we calculate that the vehicle can be around $27 and $33 million (€25 and €30 million),” explained Josep Lluís Falcó, founding partner of Genesis Biomed. The company co-finances biotech companies, especially in the initial stages. For the moment, the company has committed $2,2 million (€2 million) through its first vehicle, Genesis Ventures, through which it has participated in two different projects.

One of the last projects in which it has participated is that of DropLite, a spin-off from Icfo, which is developing an in vitro diagnostic device that allows the detection and monitoring, in a quantitative manner, of different pathological agents in humans and animals. The consulting company has participated with an investment of $55,000 (€50,000), explained the manager.

Breaking news from the biotech sector, the latest articles on biotech industry leaders and other financial headlines – get access to these, and more, with the Born2Invest mobile app.

Genesis Biomed committed $2,2 million (€2 million) to biomedicine projects

The consultancy, which had a turnover of $882,524 (€800,000) last year alone, plans to participate in at least two projects during 2020, which would complete the $2,2 million (€2 million) investment it has committed to. These initiatives will be added to the rounds in which Genesis Biomed has already participated, with companies such as Peptomyc or Anaconda Biomed.

As a result of the growth of projects, the consultancy company has opened a new office in Madrid, specifically, at 25 Calle Velázquez. Three people – a manager and two consultants – are expected to join this office in February. Lluís Falcó explains: “25% of our projects are carried out in Madrid and that is why we have taken this decision.” The executive also stated: “In the capital, there is much more critical mass, but the local biotech sector is not as structured.”

Quality Pharma ‘start-up’ was launched through the Genesis Biomeds investment fund

In 2018, Genesis Biomed launched the Quality Pharma Medtech startup through its investment fund. With an investment of $110,316 (€100,000), the company is the first spin-off to be launched within the framework of the innovation initiatives of EIT Health, a business conglomerate in the field of healthcare made up of forty companies from different European countries.

Lluís Falcó, doctor in Chemistry from the IQS School of Engineering in Sarriá, began his career at Sanofi, and later worked at the pharmaceutical company Ferrer. Over the last ten years, Falcó has founded startups such as Transplant Biomedicals and has been an observer on the board of directors of companies such as Anaconda Biomed or GlyCardial Diagnostics.

In Falcó’s words, the Spanish biotechnology sector lacks “more success stories, more specialized and larger investors,” and the work of transfer offices should be “further encouraged.”

__

(Featured image by Hans Reniers via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce., a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.